Multiple Myeloma

Oct 04, 2024

7 Companies at the Forefront of Trispecific Antibody Development

Sep 24, 2024

Zevra’s MIPLYFFA Niemann-Pick Disease Approval; FASENRA Approved for Eosinophilic Granulomatosis; Sanofi’s SARCLISA Gets Multiple Myeloma Approval; RYBREVANT Combo Gets FDA Nod for EGFR Lung Cancer; UCB’s BIMZELX Receives Multiple Approval from the FDA

Sep 24, 2024

Unleashing the Potential: CD38 Directed Therapies Revolutionize Multiple Myeloma Treatment

Aug 05, 2024

DARZALEX FASPRO Regimen Approval: Johnson & Johnson Howling Success in Multiple Myeloma

Jul 30, 2024

The Changing Landscape of Multiple Myeloma Therapies Market

Jul 25, 2024

CELMoDs – A Worthy Successor to REVLIMID?

Jul 25, 2024

BMS Vs. Janssen: Which Company Will Dominate The Multiple Myeloma Treatment Market This Decade?

Jul 24, 2024

Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes

Jul 24, 2024

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Jul 23, 2024

CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy 

Newsletter/Whitepaper